What does this research mean for the field?

The activated coagulation time (ACT) strongly correlates with APTT and provides an accurate assessment of anticoagulation status during PTCA, though a standard 10,000 U heparin bolus rarely achieves a target ACT > 300 seconds using the HemoTec system. Novelty: ClaimNovelty.INCREMENTAL. Consensus alignment: ConsensusAlignment.NEUTRAL.

August 1, 1992

Activated clotting times and activated partial thromboplastin times in patients undergoing coronary angioplasty who receive bolus doses of heparin

Structured PICO

What is the anticoagulant effect of a 10,000 U heparin bolus and the correlation between ACT and APTT in patients undergoing PTCA?

Population

545 unselected patients undergoing percutaneous transluminal coronary angioplasty (PTCA)

Intervention

10,000 U bolus of heparin

Outcome

Anticoagulant effect measured by activated coagulation time (ACT) and correlation with activated partial thromboplastin time (APTT)surrogate

ACT provides an accurate and reliable assessment of anticoagulation status that correlates strongly with APTT in patients undergoing PTCA, though a 10,000 U heparin bolus infrequently achieves an ACT >300 sec using the HemoTec system.

Abstract

Abstract The accurate assessment of coagulation status is an important part of interventional procedures performed in the cardiac catheterization laboratory. While the traditional clinical means of assessing heparin anticoagulation has been with the activated partial thromboplastin time (APTT), the activated coagulation time (ACT) has come into widespread use in the catheterization laboratory as an assay of whole blood clotting time which can be performed rapidly at the bedside. The purpose of the present study was to (1) assess the anticoagulant effect of a 10,000 U bolus of heparin in PTCA patients and (2) document the relationship between ACTs and APTTs in a subset of these patients. Baseline and postheparin ACTs were measured using a HemoTec coagulation timer in 545 unselected PTCA patients. The average baseline ACT was 120 ± 22 sec. After a 10,000 U bolus of heparin the average ACT was 249 ± 44 sec; 58% of patients had an ACT 300 sec. A total of 175 paired ACT and APTT measurements were obtained in a random subset of these patients at baseline, after heparinization, and at 4–6 hr intervals after the procedure. The APTT was limited by absolute upper and lower limits of 150 and 22 sec; there were no such limits on the ACT. When limiting values were excluded, there was a strong overall correlation between ACT and APTT measurements ( r = 0.92, p 0.001). We conclude that the activated coagulation time provides an accurate and reliable assessment of anticoagulation status. This test appears to be ideally suited for patients undergoing interventional procedures. There are, however, substantial differences in the automated systems currently in clinical use. The percent of patients achieving a target ACT of greater than 300 sec, as measured by a HemoTec system, after a 10,000 U bolus of heparin is low. These results are not extrapolatable to other ACT measurement techniques. © 1992 Wiley‐Liss, Inc.

Ask AI

Helpful

Bookmark